Down 29.2% in 4 Weeks, Here's Why NeoGenomics (NEO) Looks Ripe for a Turnaround

Group 1 - NeoGenomics (NEO) has experienced a significant decline of 29.2% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for NEO is currently at 25.23, suggesting that the heavy selling pressure may be exhausting itself [5] - There is a strong consensus among Wall Street analysts that NEO will report better earnings than previously predicted, with a 1.4% increase in the consensus EPS estimate over the last 30 days [6] Group 2 - NEO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [7]